Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Anca D Askanase, Enxu Zhao, Julie Zhu, Roman Bilyk, Richard A Furie, Anca D Askanase, Enxu Zhao, Julie Zhu, Roman Bilyk, Richard A Furie
Abstract
Introduction: We assessed the efficacy and safety of repository corticotropin injection (RCI; Acthar® Gel) for persistently active systemic lupus erythematosus (SLE) despite use of moderate-dose glucocorticoids.
Methods: This multicenter, double-blind, randomized, placebo-controlled study enrolled patients ≥ 18 years with active SLE and moderate to severe rash and/or arthritis despite stable glucocorticoid doses (7.5-30 mg/day prednisone equivalent) and antimalarials for ≥ 4 weeks and/or immunosuppressants for ≥ 8 weeks before screening. Stable glucocorticoid doses were required through week 16 with optional taper from weeks 16 to 24. Patients were randomized (1:1) to 80 U RCI subcutaneously or placebo every other day to week 4, then twice weekly to week 24. Endpoints included the proportion of SLE Responder Index (SRI)-4 responders at week 16; changes from baseline to week 16 in 28 Swollen Joint Count/Tender Joint Count (28 SJC/TJC) and Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)-Activity score; and changes from baseline to week 24 in inflammatory cytokines. Safety was assessed by adverse events.
Results: In the modified intention-to-treat population (RCI, n = 84; placebo, n = 85), the proportion of SRI-4 responders at week 16 was not significantly different between groups (RCI, 47.6%; placebo, 43.5%; OR [95% CI] 1.2 [0.6 to 2.2]; p = 0.5762). RCI treatment resulted in a reduction from baseline to week 16 in 28 SJC/TJC and CLASI-Activity score and from baseline to week 8 in a proliferation-inducing ligand cytokine. Post hoc analyses demonstrated a greater proportion of BILAG-based Combined Lupus Assessment responders for RCI than placebo at weeks 4, 12, and 20 and greater SRI-4 response in RCI-treated patients with baseline SLE Disease Activity Index-2000 ≥ 10 and CLASI-Activity ≥ 11. No new safety signals were identified.
Conclusions: Despite failure to achieve the primary endpoint, these results support the utility of RCI for treating persistently active SLE.
Trial registration: ClinicalTrials.gov identifier NCT02953821.
Keywords: Acthar Gel; Autoimmune disease; Clinical trial; Corticosteroid; Glucocorticoid; Inflammation; Repository corticotropin injection; Systemic lupus erythematosus.
Figures
References
- Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110–2121. doi: 10.1056/NEJMra1100359.
- Hruskova Z, Tesar V. Lessons learned from the failure of several recent trials with biologic treatment in systemic lupus erythematosus. Expert Opin Biol Ther. 2018;18(9):989–996. doi: 10.1080/14712598.2018.1504918.
- Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745. doi: 10.1136/annrheumdis-2019-215089.
- Acthar Gel [package insert]. Bedminster, NJ: Mallinckrodt ARD LLC; 2019.
- Catania A, Lonati C, Sordi A, Carlin A, Leonardi P, Gatti S. The melanocortin system in control of inflammation. Sci World J. 2010;10:1840–1853. doi: 10.1100/tsw.2010.173.
- Ahmed TJ, Montero-Melendez T, Perretti M, Pitzalis C. Curbing inflammation through endogenous pathways: focus on melanocortin peptides. Int J Inflam. 2013;2013:985815.
- Caruso C, Carniglia L, Durand D, Scimonelli TN, Lasaga M. Astrocytes: new targets of melanocortin 4 receptor actions. J Mol Endocrinol. 2013;51(2):R33–50. doi: 10.1530/JME-13-0064.
- Decker DA, Grant C, Oh L, Becker PM, Young D, Jordan S. Immunomodulatory effects of H.P. Acthar Gel on B cell development in the NZB/W F1 mouse model of systemic lupus erythematosus. Lupus. 2014;23(8):802–812. doi: 10.1177/0961203314531840.
- Montero-Melendez T. ACTH: the forgotten therapy. Semin Immunol. 2015;27(3):216–226. doi: 10.1016/j.smim.2015.02.003.
- Fiechtner JJ, Montroy T. Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trial. Lupus. 2014;23(9):905–912. doi: 10.1177/0961203314532562.
- Furie R, Mitrane M, Zhao E, Das M, Li D, Becker PM. Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a phase 4, randomised, controlled pilot study. Lupus Sci Med. 2016;3(1):e000180. doi: 10.1136/lupus-2016-000180.
- Furie RA, Mitrane M, Zhao E, Becker PM. Repository corticotropin injection in patients with persistently active SLE requiring corticosteroids: post hoc analysis of results from a two-part, 52-week pilot study. Lupus Sci Med. 2017;4(1):e000240. doi: 10.1136/lupus-2017-000240.
- Askanase AD, Zhao E, Zhu J, Connolly-Strong E, Furie RA. Acthar Gel (repository corticotropin injection) for persistently active systemic lupus erythematosus: study design and baseline characteristics from a multicenter, randomized, double-blind, placebo-controlled trial. Lupus Sci Med. 2020;7(1):e000383. doi: 10.1136/lupus-2020-000383.
- Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi: 10.1002/art.1780400928.
- Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288–291.
- Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005;44(7):902–906. doi: 10.1093/rheumatology/keh624.
- Klein RS, Morganroth PA, Werth VP. Cutaneous lupus and the Cutaneous Lupus Erythematosus Disease Drea and Severity Index instrument. Rheum Dis Clin N Am. 2010;36(1):33–51. doi: 10.1016/j.rdc.2009.12.001.
- Petri M, Buyon J, Kim M. Classification and definition of major flares in SLE clinical trials. Lupus. 1999;8(8):685–691. doi: 10.1191/096120399680411281.
- Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005;142(12 Pt 1):953–962. doi: 10.7326/0003-4819-142-12_Part_1-200506210-00004.
- Yee CS, Cresswell L, Farewell V, et al. Numerical scoring for the BILAG-2004 index. Rheumatology (Oxford) 2010;49(9):1665–1669. doi: 10.1093/rheumatology/keq026.
- Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009;61(9):1143–1151. doi: 10.1002/art.24698.
- Wallace DJ, Strand V, Furie R, et al (2011) Evaluation of treatment success in systemic lupus erythematosus clinical trials: development of the British Isles Lupus Assessment Group-based composite lupus assessment endpoint. Presented at: ACR: Poster 2265
- Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol. 2009;9(7):491–502. doi: 10.1038/nri2572.
- Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019;1(4):e208–e219. doi: 10.1016/S2665-9913(19)30076-1.
- van Vollenhoven RF, Hahn BH, Tsokos GC, et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet. 2018;392(10155):1330–1339. doi: 10.1016/S0140-6736(18)32167-6.
Source: PubMed